Table 2.
Summary of key phase III clinical trial data for secukinumab
| Study | Outcome measure (week 12) | Secukinumab 300 mg | Secukinumab 150 mg | Placebo | Etanercept 50 mg | Ustekinumab |
|---|---|---|---|---|---|---|
| ERASURE [62] | PASI 75 | 200/245 (81.6%) | 174/243 (71.6%) | 11/246 (4.5%) | ||
| Response of 0 or 1 on modified IGA | 160/245 (65.3%) | 125/244 (51.2%) | 6/246 (2.4%) | |||
| FIXTURE [62] | PASI 75 | 249/323 (77.1%)* | 219/327 (67.0%) | 16/324 (4.9%) | 142/323 (44.0%) | |
| Response of 0 or 1 on modified IGA | 202/323 (62.5%) | 167/327 (51.1%) | 9/324 (2.8%) | 88/323 (27.2%) | ||
| FEATURE [64] | PASI 75 | 44/59 (75%) | 41/59 (69%) | 0/59 (0%) | ||
| Clear or almost clear on modified IGA | 40/59 (68%) | 31/59 (53%) | 0/59 (0%) | |||
| JUNCTURE [63] | PASI 75 | 52/60 (87%) | 43/61 (70%) | 2/61 (3%) | ||
| Clear or almost clear on modified IGA | 44/60 (73%) | 32/61 (52%) | 0/61 (0%) | |||
| CLEAR [65] | PASI 90 (week 16) | 264/334 (79.0%)** | 193/335 (57.6%) |
IGA Investigators Global Assessment, PASI Psoriasis Area and Severity Index
* P < 0.001 vs. etanercept and placebo; ** P < 0.0001 vs. ustekinumab